Guoman Tower Hotel
St Katharine’s Way
London E1W 1LD, UK

Over BioBusiness 8 years has brought together over 2,500 business development professionals and CEOs of the pharmaceutical industry and biotechnology, as well as key health investors. Discounted biobusiness 2009 Show and experts from the pharmaceutical industry leader such as GlaxoSmithKline, Merck, Bayer Schering, Pfizer and Astellas. With generics threaten oil and M & A at all scales on the agendas of industry, delegates left with the necessary contacts to secure business relationships and that it is essential to achieve success in 2009. With a reading of the faculty of speakers like a who’s who of the pharmaceutical association, companies of biodiversity by 2010 is to consolidate its place as the highest level and effective business meeting in Europe. As the recession of the moment, both pharmaceutical and biotechnology are having to make difficult decisions about the events that produce the best results for their organizations. That’s why we made biobusiness and easy choice for you.

With a reading of the faculty of speakers like a who’s who of the pharmaceutical association, companies of biodiversity by 2010 is to consolidate its place as the highest level and effective business meeting in Europe. As the recession of the moment, both pharmaceutical and biotechnology are having to make difficult decisions about the events that produce the best results for their organizations. That’s why we made the choice biobusiness and easy for you:

1. Most speaker line high in Europe. Where else could you hear from (and meet with) most high-level speakers from Pharma top 10? Register now to make sure it is in this high-level
2. Even more effective to establish informal networks. Biobusiness attendees return year after year because they know they will have more opportunities to meet with their high level partners elsewhere. Catch up with colleagues over coffee and make new acquaintances over dinner
3. BioBusiness Program. We control the content of the agenda for biodiversity business to ensure maximum added value to their time at the conference. With high-level roundtables, case studies and insights, you must carefully plan its network to take everything in!
4. We limit the number of attendees to biodiversity business to ensure the event remains intimate and effective networking. Nobody wants to spend his days of fighting through crowds of people biobusiness irrelevant and out cuts to help ensure that all their conversations have a business objective in mind.
5.We have reviewed our 1-2-1 technology to make it even more effective this year. Be sure to book their meetings before the conference so that you can reach with its most important meetings already aligned.

Time and time again, BioBusiness attendees come back to the conference to make the most of the unique and intimate networking at the conference. No other event offers such a high concentration of senior decision makers in one place. With attendee numbers limited to under 300 and only the most senior partnering professionals invited, you’ll find yourself making valuable connections right through the day, from morning coffee to the evening cocktail receptions. We cap the numbers of service providers at the conference to make sure that everyone you meet will share your goals and be able to discuss meaningful deals. Although you can take advantage of the one-to-one sessions throughout the conference, you’ll also find yourself getting into longer, more productive meetings on an informal basis over the course of the two days.

Event Agenda

Conference Day One – 19th January 2010

08.00 – Registration and Morning Coffee

09.00 – Chair’s Opening Remarks
Klaus Wilgenbus, SVP Licensing, Boehringer Ingelheim
Chairman’s Welcome Address

09.15 – Bayer/Algeta: A Win-Win Deal Around A Cancer Drug With Block-Buster Potential
Gulzar Sandhu, Vice President, Global Licensing, Specialty Medicine
Roger Harrison, CBO, Algeta

* for the deal and mapping how the terms were put together
* Overcoming the challenges faced in agreeing a long-term strategy and finding the ‘best fit’ solution for all parties
* Planning a collaborative approach to research and achieving balance in terms of funding, control, and reward
* Finding a mutually acceptable set of financial terms including upfront payments, milestones and royalties
* Key challenges faced by both parties in progressing and concluding negotiations

10.00 – Examining The Effects Of Global Social And Economic Trends On The Development Of The Pharma Industry And Predicting How The Sector Will Change Over The Next 5 Years

* Recession proof? Measuring the effect of the economic slowdown on the pharma industry
* Charting the rise of emerging markets and pharma’s plans to deploy resource in the area in response to growing demand
* Establishing how regulators’ attitudes to swine flu vaccine approval will affect subsequent pandemic planning procedures
* Overcoming the threat of generics and setting realistic goals for getting new drugs to market to grow profits

10.30 – Deal Case Study: Merck/Schering Plough – Discussing The Strategic Benefits Of Merging Two Commercial Pipelines And Putting In Place Plans For Effective Integration
Barbara Yanni, VP and Chief Licensing Officer, Merck & Co., Inc.

* Identifying the factors which made this mega-merger timely
* Pinpointing the geographical and therapeutic advantages to be gained from a large-scale merger
* Laying the foundations for a partnership which will support the end goals of the enlarged organisation
* Putting in place timelines for integration to deliver positive results as quickly as possible
Barbara Yanni is Vice President and Chief Licensing Officer of Merck & Co., Inc. She leads the Corporate Licensing group which is responsible for negotiating agreements to acquire compounds, programs and new technologies to complement Merck’s research programs and pipeline. Barbara works closely with her scientific and marketing colleagues at Merck to ensure that the company has access to discoveries that will enhance Merck’s ability to bring medicines to patients. Barbara and her team have [ read more ...]

11:00 -Morning Coffee

11.30 – Deal Case Study: GSK/Chroma – Using ESM Technology To Drive A Multi-Level Relationship
Shelagh Wilson, Vice President, Head of CEEDD, GSK

* Identifying the drivers for GSK’s interest in ESM Technology
* Investigating the strategic and scientific goals of the collaboration
* Evolving and achieving partnership goals to ensure maximum benefit for both partners

12.15 – Panel Discussion: How Successful Is Pharma Partnering? Reviewing The Outcome Of Pharma Partnering Across The Industry Over The Past 10 Years And Determining If The Current Model Will Sustain Or Inhibit Growth In Future
Tony Rosenberg, SVP BD&L, Novartis
Klaus Wilgenbus, SVP Licensing, Boehringer Ingelheim
Carlos de Sousa, VP Business Development, Nycomed
Dan Zabrowski, Head of Worldwide Licensing, Roche
John Goddard, Senior VP Strategic Planning and Business Development, AstraZeneca

* Identifying the successful partnerships and uncovering the cost of failed alliances
* The role of big pharma – can pharma survive as a marketing vehicle rather than as an innovator?
* Do mega-mergers drive profits or stifle innovation? How can they be used as a tool for organic growth?
* How does pharma need to evolve to ensure success in the next 10 years?

Tony Rosenberg is Novartis Head of Business Development and Licensing. He joined Sandoz in 1980, holding leadership positions in sales, marketing, business development and strategic planning. In 1994 he moved to Basel and served in various positions, including Novartis Head Global Marketing Primary Care and Global Head of Transplant and Immunology.

Carlos de Sousa is Vice President Licensing at Nycomed and responsible for the company’s international in-licensing activities. He joined Nycomed February 2009 from Newron Pharmaceuticals SpA in Italy, where he was Chief Business Officer responsible for the company’s growth strategy, including its in- and out-licensing, and mergers & acquisitions activities. Previously, he was Global Head of Business Development and Licensing at Schwarz Pharma AG in Germany. Prior to that Carlos de Sousa [ read more ...]

Dr Dan Zabrowski is a member of the Roche Pharma Executive Committee and has been Global Head of Pharma Partnering since July 2007, based at Roche’s headquarters in Basel, Switzerland. Since joining Roche in 1993, he has held a number of leadership roles including Global Head of Pharma Development Operations and Global Head of Pharma Development Regulatory. Prior to that he was Executive Director, Drug Regulatory Affairs at Syntex, which was integrated into the Roche Group in 1994. Dan was [ read more ...]

John Goddard was appointed Senior Vice President and Head of Strategic Planning and Business Development for AstraZeneca in May 2006 and is based in London. In addition, John is Chairman of Aptium Healthcare Inc., a wholly owned subsidiary based in Los Angeles, which manages the provision of outpatient cancer care and Chairman of AstraTech another wholly owned subsidiary, which develops, manufactures and markets advanced healthcare devices for single use and dental implants. John is also a [ read more ...]

12:45 – Address: Understanding How The FSA Is Responding To The Needs Of The Buy And Sell Side in Japan
Address: Understanding How The FSA Is Responding To The Needs Of The Buy And Sell Side in Japan

13:15 – LUNCH

14.30 Investment Challenge #1
Janette Dean, Senior Director Business Development, BMS
Denise Goode, Executive Director, Strategic Transactions
Join 3 biotech CEOs as they pitch their products to a board of Big Pharma experts. Find out how biotech pitches are received by their potential partners of choice and hear live feedback to help you improve your own pitch.   Judges:
photo

Janette Dean
Janette is Executive Director, Strategic Transactions at Bristol-Myers Squibb. Her recent collaboration was with Astra Zeneca for the co development and commercialization of Saxagliptin and Dapagliflozin. Other European deals include those with Medivir AB, Sweden, Solvay Pharmaceuticals, Belgium and Nerviano Medical, Italy. Janette is a member of the Chartered Institute of Management Accountants.

Funding Focus
2009 hasn’t been an easy year for biotech funding. Join our panels of experts as they look back at successful strategies for continued funding over the past 12 months and explain how the sector is likely to fare in 2010.

16.00 – Alternative Funding Strategies 2010: Locating New Sources of Funding In A Static Market To Drive The Development Of Your Pipeline
Onno van de Stolpe, CEO, Galapagos
Edwin Moses, CEO, Ablynx
Chris Hentschel, CEO, MMV

* Are traditional funding methods still available and, if so, how far can they be relied upon to support your business in 2010?
* Looking for new funding from
o Business angels
o Charities
o Research funds
* Where and when to look for governmental support for your research
* Exploring new commercial opportunities to enable your primary research focus to continue

Onno van de Stolpe founded Galapagos 1999 and has grown the Company to its current level of 500 employees. Galapagos is an integrated drug discovery company with a number of internal programs and a large service division BioFocus. For its internal programs, Galapagos has Merck, GSK, Lily and J&J as alliance partners. In these programs Galapagos is responsible for delivering clinical molecules after which the partner has licensing options. Before Galapagos, Onno established the European [ read more ...]

Over the past five years Edwin has played an important role at Board level (primarily as Chairman) in over 15 European life science companies. During this time he has been involved in financing rounds totaling in excess of €200M, a series of M&A transactions and three IPO’s. In March 2006, Edwin accepted the offer by Ablynx’s Board to extend his role as Chairman to include that of Chief Executive Officer. Edwin has been Chairman of Ablynx since 2004.

Dr. Chris Hentschel, President and CEO, Medicines for Malaria Venture (MMV), SwitzerlandA bio-pharmaceutical executive with more than 25 years’ international R&D and technology transfer management experience in both private and public sectors. Doctorate in biochemistry, King’s College, London. Early career focused on basic biomedical research, including as a Fogarty Fellow at NIH, USA. Chris has been CEO of MMV since 2000.

16:00 – Break
Break

16.40 – Funding Case Study: How Galapagos Leveraged Its Alliance Strategy To Capitalise on Its Technology and Build a Promising Pipeline
Onno van de Stolpe, CEO, Galapagos

* How Galapagos captured the #5 European biotech spot
* How to balance a portfolio: what to partner, what to keep
* How to develop new mode of actions, without going bankrupt
Onno van de Stolpe founded Galapagos 1999 and has grown the Company to its current level of 500 employees. Galapagos is an integrated drug discovery company with a number of internal programs and a large service division BioFocus. For its internal programs, Galapagos has Merck, GSK, Lily and J&J as alliance partners. In these programs Galapagos is responsible for delivering clinical molecules after which the partner has licensing options. Before Galapagos, Onno established the European [ read more ...]

17.10 The Funding Forecast: Mapping How Biotech Funding Will Look In 2010 And 2015 To Help You Plan Your Financing Strategy Over The Next 5 Years
Kate Bingham, Managing Partner, SVLSA
Patrick Lee, Partner, Ares Life Sciences
Denise Pollard-Knight, Managing Director, Nomura

* VC outlook – when will venture money be available again and how will investment criteria have changed?
* How will big pharma’s financing arms develop over the next 5 years and what role will they play in ensuring good research is supported?
* Exit strategies – will IPOs be a viable option again in the near future and how can you prepare for them?

Kate Bingham joined SVLS in 1991. Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden andGermany. She has been responsible for past investments in Alantos, Auxilium, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed and current investments including ESBATech, EUSA and RespiVert.

Patrick Lee has been an investor since 1999 as a general partner with Advent Venture Partners where he led investments in health care companies. Before that, he held various executive positions in marketing, product development and business development at Rhone Poulenc. As Group Vice President, Mergers and Acquisitions, he was actively involved in the creation of Aventis through Rhone Poulenc’s merger with Hoechst. He also worked at Baxter and Booz Allen and Hamilton.

Denise has been responsible for leading Nomura’s life science investment activities since joining in 1999 and has over 12 years experience as a venture capitalist. Prior to joining Nomura she was an investment manager in the Bioscience Unit of Rothschild Asset Management, managing investments in private and public biotechnology companies. Denise has held senior management positions in pharmaceutical R&D and in strategic consulting. Denise holds a PhD and BSc (Hons) from Birmingham [ read more ...]

17.55 – BioBusiness 2010 Drinks Reception
BioBusiness 2010 Drinks Reception

19.00 – BioBusiness Networking Dinner

Conference Day 2 – 20th January 2010

8:30 – Registration and Morning Coffee

9:00 – Chair’s Opening Remarks

9:10 – Deal Case Study: Roche/Synosia – Creating A Broad Partnership To Develop Promising Drug Candidates
Christoph Sarry, Global Alliance Director, Roche
Ian Massey, CEO, Synosia

* Understanding the market factors and individual drivers which led to a CNS-focussed partnership
* Determining how each organisation’s needs and objectives were met in the negotiation process
* Examining how the partnership can be evolved to support both parties ongoing objectives

09.50 – Biotech CEO Panel: Examining The Biotech Reaction To The Megamergers Of 2009 And Expectations For 2010
Kees Been, CEO, Envivo Pharma
Simon Moroney, CEO, Morphosys
* Assessing biotech reactions to the large-scale M&A activity in 2009 – what opportunities does this present to the industry?
* Gauging biotech reactions to the lack of financing options available – what will the implications be for your research?
* Connecting your research with pharma demands and ensuring new research meets current commercial needs

Kees is President and CEO of EnVivo Pharmaceuticals, which is pursuing a diversified portfolio of five clinical and pre-clinical programs in the field of cognitive and neuro-degenerative disorders, with a main focus on Alzheimer’s disease and Schizophrenia. Prior to joining EnVivo, Kees was CEO of Bionaut Pharmaceuticals, a biotechnology company using a proprietary cell-based discovery platform to advance drug candidates for cancer and inflammation. Before that, Kees spent four years at Biogen [ read more ...]

Dr. Simon Moroney is CEO of MorphoSys AG and one of the Company’s co-founders. Prior to co-founding MorphoSys, Dr Moroney held positions in the Department of Pharmacology, University of Cambridge, Cambridge, UK (1991- 1992); as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada (1989 – 1990) and as Associate in the Chemistry Department of the Eidgenössische Technische Hochschule (ETH), in Zurich, Switzerland (1986 – 1989), where he also held [ read more ...]

10.30 – Big Pharma Panel: What Is Big Pharma Looking For In 2010 And How Will Recent Mergers Affect The Way You Do Business With Them?
Jules Musing, Vice President, Business Development and Licensing, J&J
Yetunde Taiwo, Senior Director, Eli Lilly and Company
Ulrich Koch, Head of Global Licensing, Bayer Schering Pharma
Denise Goode, Executive Director, Strategic Transactions
* Identifying key therapeutic areas and regions which will form a focus for big pharma in 2010
* Dos and don’ts of pitching big pharma – how should you present your research?
* Ongoing relationships with enlarged organisations – what impact will mergers have on pharma’s appetite for new deals?

Dr. Yetunde Taiwo is currently Senior Director of Global External R&D at Eli Lilly and Company, supporting Lilly’s external innovation efforts. She leads a multidisciplinary team responsible for the identification and scientific evaluation of external innovation in the areas of Musculoskeletal and Auto-immune Diseases, Inflammation, Technologies, Biomarkers and new disease areas outside Lilly’s current Therapeutic areas.

Ulrich Koch joined Schering AG in Berlin, Germany, in 1982 and had responsibilities within Sales, Marketing, Strategic Planning and Licensing. Prior to the acquisition by Bayer he was Head of Business Development at Schering. After the acquisition Ulrich had responsibility for licensing activities of BSP’s Business Units. Currently, he is responsible for Bayer Schering Pharma’s licensing activities in Emerging Markets. Ulrich worked and lived 4 years in the United Kingdom, and 4 years in the [ read more ...]

11.15 – Mid-Morning Coffee

12.00 – Investment Challenge #2
Jules Musing, Vice President, Business Development and Licensing, J&J
Join 3 biotech CEOs as they pitch their products to a board of Big Pharma experts. Find out how biotech pitches are received by their potential partners of choice and hear live feedback to help you improve your own pitch

13.00 – Networking Lunch

Early-Stage Deals Focus
Based on research with over 73 European and US biotechs, we’ve put together this in-depth focus session to offer biotech and pharma involved in early-stage deals a forum to meet and discuss their needs. Feedback from biotechs with early-stage products in their pipelines was that it can be hard to identify the big pharma partners you need to meet with, and that pharma needs and expectations can be unclear. With that in mind, we’ve put together this unique afternoon dedicated to helping innovate biotechs pinpoint the partners they need to meet with and giving examples of how successful deals can be done.

14.00 – Early-Stage Deals, A Win-Win For Big Pharma And Founders – The VC Perspective
Dr. Peter Neubeck, Principal, TVM Capital
* Increasingly, innovative early-stage deals take the stage of biotech deal-making
* For both Big Pharma and for the founders / the early-stage biotech company, this deal type can be highly attractive, but what about the VC investor?

14.30 Deal Case Study: BTG/Onyx – Identifying The Potential In Novel Cancer Compounds And Putting In Place A Deal To Deliver Consistent Results
Lee Holmes, Senior Manager Business Development, BTG
Juergen Lasowski, SVP Corporate Development, Onyx
* Assessing the impact a preclinical anticancer compound will have on Onyx’s pipeline
* Agreeing upfront payments, milestones and royalties to suit both partners
* Identifying partners’ strengths in drug development and commercialization
* Fitting this deal into the long-term strategies of both partners and how it can be leveraged further to yield ongoing benefits

15.10 Big Pharma In Early-Stage Deals: Identifying The Right Big Pharma Contact For Your Pre-Clinical Product And Ensuring Your Offering Meets Their Needs
Peter Halle, Vice President Early Stage Licensing, Merck Serono
Margaret Beer, Senior Director and Head Licensing and External Research, Europe, Merck and Co., Inc.
* Making contact: how should you research and approach the correct decision maker in your target big pharma company?
* Taking into account critical factors when getting in touch:
o Regional responsibilities
o Therapeutic focus
* Differentiating between the gatekeeper and the final decision maker and who to approach first
* Mapping pharma requirements within pre-clinical research to better understand how your product could be used
* Tying your early-stage research to commercial drivers to ensure a fit with your partner’s goals

Margaret Beer is one of the founding members of the team responsible for the development of Merck’s anti-migraine drug MAXALT and was involved in the project during the basic research stage through to the launch in 1997. Her other main areas of research interest include depression, anxiety and multiple sclerosis. Margaret joined the Worldwide Licensing and External Research, Europe, group, under the leadership of Dr Ray Hill, in 2003. This group was established in 2002 specifically in [ read more ...]

15.40 – Early-Stage Valuation: Balancing Risk And Reward To Accurately Value Your Pre-Clinical Product
* Examining precedents in the market to estimate what your product is worth
* Calculating the long-term potential of a product in comparison to the statistical failure rates
* Comparing the benefits of static and dynamic valuations and understanding the role they play in pharma’s overall valuation policy

16.10 – Afternoon Coffee

16.45 – Deal Case Study: Eli Lilly/Galapagos – Identifying The Drivers For An Early-Stage Deal And Building A Partnership To Support Successful Development
Onno van de Stolpe, CEO, Galapagos
Yetunde Taiwo, Senior Director, Eli Lilly and Company
* Mitigating risk through a comprehensive collaboration strategy to support research objectives
* Leveraging platforms to explore new indications and evolve the partnership

Onno van de Stolpe founded Galapagos 1999 and has grown the Company to its current level of 500 employees. Galapagos is an integrated drug discovery company with a number of internal programs and a large service division BioFocus. For its internal programs, Galapagos has Merck, GSK, Lily and J&J as alliance partners. In these programs Galapagos is responsible for delivering clinical molecules after which the partner has licensing options. Before Galapagos, Onno established the European [ read more ...]

Dr. Yetunde Taiwo is currently Senior Director of Global External R&D at Eli Lilly and Company, supporting Lilly’s external innovation efforts. She leads a multidisciplinary team responsible for the identification and scientific evaluation of external innovation in the areas of Musculoskeletal and Auto-immune Diseases, Inflammation, Technologies, Biomarkers and new disease areas outside Lilly’s current Therapeutic areas.

16.45 – Deal Case Study: Eli Lilly/Galapagos – Identifying The Drivers For An Early-Stage Deal And Building A Partnership To Support Successful Development
Onno van de Stolpe, CEO, Galapagos
Yetunde Taiwo, Senior Director, Eli Lilly and Company

* Mitigating risk through a comprehensive collaboration strategy to support research objectives
* Leveraging platforms to explore new indications and evolve the partnership

Onno van de Stolpe founded Galapagos 1999 and has grown the Company to its current level of 500 employees. Galapagos is an integrated drug discovery company with a number of internal programs and a large service division BioFocus. For its internal programs, Galapagos has Merck, GSK, Lily and J&J as alliance partners. In these programs Galapagos is responsible for delivering clinical molecules after which the partner has licensing options. Before Galapagos, Onno established the European [ read more ...]

Dr. Yetunde Taiwo is currently Senior Director of Global External R&D at Eli Lilly and Company, supporting Lilly’s external innovation efforts. She leads a multidisciplinary team responsible for the identification and scientific evaluation of external innovation in the areas of Musculoskeletal and Auto-immune Diseases, Inflammation, Technologies, Biomarkers and new disease areas outside Lilly’s current Therapeutic areas.

17.15 – Panel Discussion: Is A Shortage Of Late-Stage Products Driving Growth In Pre-Clinical Deals? How Can This Be Leveraged To Your Advantage?
Onno van de Stolpe, CEO, Galapagos
Roland Kozlowski, CEO, Lectus Therapeutics
Kees Lucas, Managing Director, Life Science Consultancy

Register Online

Close

Similar Events

• Pulse 2009
• Innovation 2009 Conference & Congress – Dusseldorf, Germany
• BigIdeas 2009 User Conference – Chicago, IL, USA
• Transform Your Business with Innovation Management
• Technology and Innovation Management – 3-day course in Cambridge, UK